DYN
Dyne Therapeutics, Inc. NASDAQ Listed Sep 17, 2020$17.11
-5.26%
vs $18.06
Mkt Cap $2.2B
52w Low $12.37
32.9% of range
52w High $26.78
50d MA $23.98
200d MA $19.80
P/E (TTM)
-5.1x
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.0x
ROE
-45.9%
P/FCF
-5.4x
RSI (14)
13.40
ATR (14)
$1.14
Beta
1.28
50d MA
$23.98
200d MA
$19.80
Avg Volume
2.8M
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
1560 Trapelo Road · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BMO | -0.74 | -1.08 | -45.9% | 25.10 | -2.4% | +2.5% | -2.1% | +0.2% | +2.9% | +0.8% | — |
| May 11, 2026 | BMO | -0.77 | -0.73 | +5.5% | 18.46 | +0.2% | -0.5% | +0.4% | -0.9% | -5.4% | -4.3% | — |
| May 8, 2026 | BMO | — | — | — | 17.54 | -0.3% | +0.4% | +4.8% | -0.5% | +0.4% | -0.9% | — |
| May 7, 2026 | BMO | — | — | — | 18.84 | +0.1% | -6.9% | +0.4% | +4.8% | -0.5% | +0.4% | — |
| Mar 2, 2026 | BMO | -0.74 | -0.76 | -2.7% | 16.15 | -4.1% | -9.6% | +4.3% | -0.2% | -2.2% | +19.0% | — |
| Nov 5, 2025 | BMO | -0.81 | -0.76 | +6.2% | 20.90 | +0.8% | -12.9% | +0.9% | +0.8% | +6.3% | -5.4% | — |
| Jul 28, 2025 | BMO | -0.99 | -0.97 | +2.0% | 9.31 | +2.0% | -1.2% | +7.7% | -0.6% | +2.0% | +2.0% | — |
| May 8, 2025 | BMO | -0.88 | -1.05 | -19.3% | 11.30 | +1.2% | +1.0% | +10.1% | -3.7% | -3.3% | +0.3% | — |
| Feb 27, 2025 | BMO | -0.92 | -0.88 | +4.3% | 13.17 | -0.5% | +3.3% | -9.5% | -3.5% | +2.4% | +0.5% | — |
| Nov 12, 2024 | BMO | -0.71 | -0.96 | -35.2% | 29.33 | -0.7% | +16.4% | -11.2% | -6.3% | +3.3% | +1.2% | — |
| Aug 12, 2024 | BMO | -0.72 | -0.70 | +2.8% | 43.07 | +2.7% | +1.3% | +0.6% | +4.2% | -0.8% | +1.6% | — |
| May 2, 2024 | BMO | -0.81 | -0.81 | +0.0% | 26.00 | +0.0% | +0.3% | +0.7% | -2.3% | +0.2% | +1.0% | — |
| Mar 5, 2024 | BMO | -0.92 | -1.09 | -18.5% | 25.87 | +4.3% | +3.5% | -1.3% | -4.8% | +1.6% | +6.1% | — |
| Oct 30, 2023 | BMO | -0.86 | -0.99 | -15.1% | 7.32 | -1.8% | -3.7% | +3.5% | -2.1% | +15.1% | -0.9% | — |
| Aug 3, 2023 | BMO | -0.81 | -1.08 | -33.3% | 11.50 | -0.8% | +0.4% | +0.1% | -14.1% | +6.5% | +3.2% | — |
| May 11, 2023 | AMC | -0.77 | -0.78 | -1.3% | 13.60 | +0.4% | -1.2% | +1.9% | -2.5% | +1.6% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9 | JP Morgan | Downgrade | Neutral → Underweight | $10 | $20.31 | $19.38 | -4.6% | -5.5% | -4.0% | -1.1% | +1.7% | -3.3% |
| Jul 23 | Cantor Fitzgerald | Initiates | Overweight | — | $23.21 | $22.95 | -1.1% | +2.9% | +2.3% | +4.9% | +1.1% | -3.1% |
| Jun 26 | TD Cowen | Initiates | Buy | — | $20.61 | $20.96 | +1.7% | +1.6% | +1.5% | +4.5% | -1.9% | +5.9% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $14.86 | $15.27 | +2.8% | +19.0% | +11.8% | +1.1% | -9.7% | -0.8% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.15 | $15.49 | -4.1% | -9.6% | +4.3% | -0.2% | -2.2% | +19.0% |
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.15 | $15.49 | -4.1% | -9.6% | +4.3% | -0.2% | -2.2% | +19.0% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $16.15 | $15.49 | -4.1% | -9.6% | +4.3% | -0.2% | -2.2% | +19.0% |
| Jan 20 | JP Morgan | Maintains | Neutral → Neutral | — | $16.70 | $16.52 | -1.1% | -0.7% | +5.5% | +3.3% | -0.4% | +0.0% |
| Dec 15 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.27 | $19.31 | +0.2% | +1.7% | -0.2% | -3.3% | -1.9% | +7.0% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $19.69 | $20.05 | +1.8% | -1.4% | -0.8% | +1.7% | -0.2% | -3.3% |
| Dec 10 | Oppenheimer | Upgrade | Perform → Outperform | — | $18.44 | $19.57 | +6.1% | +6.8% | -1.4% | -0.8% | +1.7% | -0.2% |
| Dec 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $22.20 | $21.41 | -3.6% | -16.9% | +6.8% | -1.4% | -0.8% | +1.7% |
| Dec 9 | Chardan Capital | Maintains | Buy → Buy | — | $22.20 | $21.41 | -3.6% | -16.9% | +6.8% | -1.4% | -0.8% | +1.7% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.28 | $21.59 | +6.5% | +9.5% | -16.9% | +6.8% | -1.4% | -0.8% |
| Nov 14 | JP Morgan | Maintains | Neutral → Neutral | — | $18.83 | $18.34 | -2.6% | -0.2% | +7.7% | +3.6% | -1.7% | -2.3% |
| Nov 12 | Oppenheimer | Maintains | Perform → Perform | — | $19.67 | $19.41 | -1.3% | -5.4% | +1.2% | -0.2% | +7.7% | +3.6% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $20.90 | $21.06 | +0.8% | -12.9% | +0.9% | +0.8% | +6.3% | -5.4% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.90 | $21.06 | +0.8% | -12.9% | +0.9% | +0.8% | +6.3% | -5.4% |
| Oct 10 | Oppenheimer | Downgrade | Outperform → Perform | — | $14.68 | $14.13 | -3.7% | -4.3% | -0.1% | +10.1% | +7.0% | -0.7% |
| Aug 25 | Raymond James | Upgrade | Outperform → Strong Buy | — | $12.58 | $13.55 | +7.7% | +3.3% | +2.9% | +1.9% | +0.8% | -1.9% |
| Aug 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.47 | $10.23 | -2.3% | +10.7% | -3.5% | -0.3% | +0.7% | +3.4% |
| Jul 31 | Stifel | Maintains | Buy → Buy | — | $9.91 | $9.80 | -1.1% | -0.6% | +2.0% | +2.0% | +2.1% | +10.7% |
| Jul 29 | Chardan Capital | Maintains | Buy → Buy | — | $9.31 | $9.50 | +2.0% | -1.2% | +7.7% | -0.6% | +2.0% | +2.0% |
| Jul 29 | RBC Capital | Maintains | Outperform → Outperform | — | $9.31 | $9.50 | +2.0% | -1.2% | +7.7% | -0.6% | +2.0% | +2.0% |
| Jul 29 | Raymond James | Maintains | Outperform → Outperform | — | $9.31 | $9.50 | +2.0% | -1.2% | +7.7% | -0.6% | +2.0% | +2.0% |
| Jul 15 | JP Morgan | Maintains | Neutral → Neutral | — | $8.91 | $9.04 | +1.5% | -7.1% | +12.7% | +0.8% | -4.0% | +1.7% |
| Jun 18 | Baird | Maintains | Outperform → Outperform | — | $10.86 | $10.79 | -0.6% | -0.7% | -4.3% | -1.6% | +4.6% | -2.0% |
| Jun 18 | Guggenheim | Maintains | Buy → Buy | — | $10.86 | $10.79 | -0.6% | -0.7% | -4.3% | -1.6% | +4.6% | -2.0% |
| Jun 17 | Chardan Capital | Maintains | Buy → Buy | — | $13.82 | $12.51 | -9.5% | -21.4% | -0.7% | -4.3% | -1.6% | +4.6% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $11.30 | $11.44 | +1.2% | +1.0% | +10.1% | -3.7% | -3.3% | +0.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.30 | $11.44 | +1.2% | +1.0% | +10.1% | -3.7% | -3.3% | +0.3% |
| Mar 21 | JP Morgan | Maintains | Neutral → Neutral | — | $12.26 | $12.14 | -1.0% | -1.5% | +2.6% | -8.0% | -1.2% | +4.8% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.05 | $12.46 | +3.4% | +2.2% | +2.2% | -1.4% | -1.1% | -1.5% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $12.05 | $12.46 | +3.4% | +2.2% | +2.2% | -1.4% | -1.1% | -1.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.17 | $13.10 | -0.5% | +3.3% | -9.5% | -3.5% | +2.4% | +0.5% |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | $13.17 | $13.10 | -0.5% | +3.3% | -9.5% | -3.5% | +2.4% | +0.5% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.17 | $13.10 | -0.5% | +3.3% | -9.5% | -3.5% | +2.4% | +0.5% |
| Jan 24 | Guggenheim | Maintains | Buy → Buy | — | $13.69 | $13.72 | +0.2% | +0.2% | -0.4% | -1.5% | +0.6% | +4.4% |
| Jan 14 | RBC Capital | Maintains | Outperform → Outperform | — | $15.29 | $15.75 | +3.0% | -1.9% | +3.6% | -5.0% | -4.3% | +3.0% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.87 | $15.80 | -0.4% | -3.7% | -1.9% | +3.6% | -5.0% | -4.3% |
| Jan 10 | Chardan Capital | Maintains | Buy → Buy | — | $23.05 | $20.00 | -13.2% | -31.1% | -3.7% | -1.9% | +3.6% | -5.0% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.05 | $20.00 | -13.2% | -31.1% | -3.7% | -1.9% | +3.6% | -5.0% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $29.33 | $29.12 | -0.7% | +16.4% | -11.2% | -6.3% | +3.3% | +1.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.33 | $29.12 | -0.7% | +16.4% | -11.2% | -6.3% | +3.3% | +1.2% |
| Oct 24 | JP Morgan | Downgrade | Overweight → Neutral | — | $32.36 | $31.33 | -3.2% | -3.9% | -1.2% | +0.2% | -1.8% | -3.4% |
| Sep 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.59 | $36.64 | +0.1% | -5.4% | -3.6% | +4.4% | -0.7% | -2.3% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.94 | $31.88 | -0.2% | +5.7% | -0.3% | -1.8% | -1.7% | -0.1% |
| Sep 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.09 | $27.77 | -39.7% | -30.7% | +5.7% | -0.3% | -1.8% | -1.7% |
| Aug 16 | Stifel | Maintains | Buy → Buy | — | $45.74 | $45.36 | -0.8% | -0.8% | +1.6% | +1.5% | +0.5% | -3.3% |
| Aug 15 | Guggenheim | Maintains | Buy → Buy | — | $43.88 | $45.01 | +2.6% | +4.2% | -0.8% | +1.6% | +1.5% | +0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cox John | CEO & President | Sell | 5,658 | $18.88 | $107K | 357,507 | -5.51% | -3.35% |
| Sep 8, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 1,290 | $18.88 | $24K | 162,564 | -5.51% | -3.35% |
| Sep 8, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 185 | $18.88 | $3K | 152,897 | -5.51% | -3.35% |
| Sep 4, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 3,745 | $24.35 | $91K | 163,854 | -5.51% | -3.35% |
| Sep 4, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 900 | $24.35 | $22K | 153,082 | -5.51% | -3.35% |
| Aug 14, 2026 | Rhodes Jason P | — | Sell | 322,465 | $25.00 | $8.1M | 428,946 | -0.57% | -0.42% |
| Aug 14, 2026 | Rhodes Jason P | — | Sell | 478,377 | $25.00 | $12.0M | 567,358 | -0.57% | -0.42% |
| Aug 14, 2026 | Rhodes Jason P | — | Sell | 1,359,674 | $25.00 | $34.0M | 2,441,454 | -0.57% | -0.42% |
| Aug 13, 2026 | Rhodes Jason P | — | Sell | 63,643 | $26.20 | $1.7M | 751,411 | -0.57% | -0.42% |
| Aug 13, 2026 | Rhodes Jason P | — | Sell | 94,415 | $26.20 | $2.5M | 1,045,735 | -0.57% | -0.42% |
| Aug 13, 2026 | Rhodes Jason P | — | Sell | 268,354 | $26.20 | $7.0M | 3,801,128 | -0.57% | -0.42% |
| Aug 13, 2026 | Cox John | CEO & President | Sell | 4,986 | $26.28 | $131K | 363,165 | -0.57% | -0.42% |
| Aug 13, 2026 | Lucera Erick | Chief Financial Officer | Sell | 1,797 | $26.28 | $47K | 119,766 | -0.57% | -0.42% |
| Aug 13, 2026 | Kerr Douglas | Chief Medical Officer | Sell | 1,556 | $26.28 | $41K | 167,599 | -0.57% | -0.42% |
| Aug 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 226 | $26.28 | $6K | 153,982 | -0.57% | -0.42% |
| Jul 27, 2026 | Kersten Dirk | — | Sell | 5,388 | $26.04 | $140K | 3,586,796 | +2.51% | +0.77% |
| Jul 27, 2026 | Kersten Dirk | — | Sell | 256,072 | $25.50 | $6.5M | 3,592,184 | +2.51% | +0.77% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 5,000 | $23.61 | $118K | 2,962 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 11,665 | $23.62 | $276K | 815,054 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 49,193 | $23.17 | $1.1M | 826,719 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 14,844 | $23.62 | $351K | 1,140,150 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 62,543 | $23.17 | $1.4M | 1,154,994 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 29,587 | $23.62 | $699K | 4,069,482 | +1.85% | +0.88% |
| Jul 7, 2026 | Rhodes Jason P | — | Sell | 124,379 | $23.17 | $2.9M | 4,099,069 | +1.85% | +0.88% |
| Jul 6, 2026 | Rhodes Jason P | — | Sell | 100,019 | $22.79 | $2.3M | 875,912 | +1.85% | +0.88% |
| Jul 6, 2026 | Rhodes Jason P | — | Sell | 127,182 | $22.79 | $2.9M | 1,217,537 | +1.85% | +0.88% |
| Jul 6, 2026 | Rhodes Jason P | — | Sell | 253,039 | $22.79 | $5.8M | 4,223,448 | +1.85% | +0.88% |
| Jun 29, 2026 | Rhodes Jason P | — | Sell | 40,702 | $21.14 | $860K | 975,931 | -1.89% | +0.00% |
| Jun 29, 2026 | Rhodes Jason P | — | Sell | 51,756 | $21.14 | $1.1M | 1,344,719 | -1.89% | +0.00% |
| Jun 29, 2026 | Rhodes Jason P | — | Sell | 102,969 | $21.14 | $2.2M | 4,476,487 | -1.89% | +0.00% |
8-K · 8.01
!! High
Dyne Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Dyne Therapeutics' DYNE-251 for Duchenne muscular dystrophy received FDA Priority Review with a January 2027 decision deadline, potentially accelerating commercialization for this rare genetic disease treatment.
Jul 20
8-K · 5.02
!!! Very High
Dyne Therapeutics, Inc. -- 8-K 5.02: Executive Change
Barry E. Greene's appointment as a Class I director at Dyne Therapeutics strengthens the company's board governance structure with new leadership oversight.
Jun 22
8-K · 1.01
! Medium
Dyne Therapeutics, Inc. -- 8-K 1.01: Financing / Debt Agreement
Dyne Therapeutics secured a $400 million financing agreement with Hercules Capital, providing significant capital to fund its clinical development and operations.
Jun 17
8-K · 8.01
!! High
Dyne Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K · 2.02
!! High
Dyne Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 11
8-K
Dyne Therapeutics, Inc. -- 8-K Filing
Dyne Therapeutics reported 2025 financial results and highlighted progress in its clinical-stage pipeline for treating genetically driven neuromuscular diseases, positioning the biotech company for upcoming regulatory submissions.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 12,404,330 | $276M | New | Jun 2026 |
| 2 | Janus Henderson Group Plc | 13,647,376 | $247M | New | Mar 2026 |
| 3 | Atlas Venture Life Science Advisors, Llc | 9,130,465 | $166M | — | Mar 2026 |
| 4 | Fmr Llc | 8,908,980 | $162M | Added | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 6,310,969 | $140M | Reduced | Jun 2026 |
| 6 | Orbis Allan Gray Ltd | 6,762,231 | $123M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 4,048,428 | $90M | Reduced | Jun 2026 |
| 8 | Jpmorgan Chase & Co | 3,253,473 | $56M | Reduced | Mar 2026 |
| 9 | Citadel Advisors Llc | 2,287,916 | $51M | Added | Jun 2026 |
| 10 | Morgan Stanley | 2,427,118 | $47M | Reduced | Dec 2025 |
| 11 | Siren, L.l.c. | 2,129,125 | $47M | New | Jun 2026 |
| 12 | Vr Adviser, Llc | 2,173,913 | $43M | — | Dec 2025 |
| 13 | Palo Alto Investors Lp | 1,647,521 | $37M | New | Jun 2026 |
| 14 | Franklin Resources Inc | 2,009,082 | $36M | — | Mar 2026 |
| 15 | Samlyn Capital, Llc | 1,922,543 | $35M | Added | Mar 2026 |
| 16 | Aberdeen Group Plc | 1,539,434 | $34M | Added | Jun 2026 |
| 17 | Deep Track Capital, Lp | 1,500,000 | $33M | New | Jun 2026 |
| 18 | Braidwell Lp | 1,478,329 | $29M | Reduced | Dec 2025 |
| 19 | Vivo Capital, Llc | 1,557,466 | $28M | New | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 1,443,313 | $26M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.20B
Enterprise Value
$1.10B
P/E (TTM)
-5.14x
Forward P/E
—
PEG Ratio
-1.90x
P/B
2.26x
P/S
—
P/FCF
-5.42x
EV/EBITDA
—
Shares Out
128.4M
Financials (TTM)
Revenue
$0
Net Income
-$519.4M
EBITDA
-$495.3M
Free Cash Flow
-$405.1M
Op Cash Flow
-$403.2M
EPS Basic
$-3.47
EPS Diluted
$-3.33
EPS Forward
$-3.16
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$1.19B
Total Liab.
$214.8M
Total Equity
$972.1M
Cash
$1.11B
LT Debt
$15.3M
Book Value/Sh
$7.57
Debt/Equity
0.02x
Current Ratio
22.25
Quick Ratio
22.25
Returns & Growth
ROE
-45.9%
ROA
-37.6%
ROIC
-41.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-3.0%
Price Returns
2W
-28.2%
1M
-30.5%
3M
-8.8%
6M
-1.3%
12M
+29.7%
Technicals
52W High
$26.78
52W Low
$12.37
50d MA
$23.98
200d MA
$19.80
RSI (14)
13.40
ATR (14)
$1.14
Beta
1.28
Avg Volume
2.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$37.60
High
$60.00
Low
$23.00
Median
$38.50
Data updated apr 25, 2026 6:12am
· Source: financialmodelingprep.com